<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393950</url>
  </required_header>
  <id_info>
    <org_study_id>3117001</org_study_id>
    <secondary_id>2014-001317-33</secondary_id>
    <nct_id>NCT02393950</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers</brief_title>
  <acronym>FIMPAM</acronym>
  <official_title>Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a dose escalation study with 8 planned dose levels. The study is a 4-period
      crossover design where each healthy volunteer will be randomised to receive three dose levels
      of ODM-106 (single doses) and one dose of placebo. The study will look at the
      pharmacokinetics (how the body handles the drug) and pharmacodynamics (how the drug affects
      the body) of ODM-106.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eight planned dose levels of ODM-106 will be compared with placebo.There will be 2 panels of
      subjects with 4 dose levels in each panel. Subjects will be randomised to receive 3 dose
      levels of active treatment (single doses) and 1 dose of placebo. The dose levels will be
      escalated from the smallest dose upwards within the study and within the study subject. A
      third panel of 8 subjects may be included to investigate further dose levels of ODM-106,
      investigate the effect of taking ODM-106 with food or to compare two different formulations
      of ODM-106. For an individual subject, the study will consist of a screening period (maximum
      4 weeks), 4 study treatment periods with a wash-out period between each study treatment
      administration and a post-treatment period of about 2 weeks.

      The study duration for an individual will be approximately 12-16 weeks. Blood samples will be
      collected for the assessment of the concentration of ODM-106 and its metabolite.Plasma
      samples and cumulative urinary samples will be collected for metabolite screening. Safety
      will be assessed by a 12-lead electrocardiogram (ECG), continuous ECG monitoring, Holter ECG,
      supine and orthostatic blood pressure and heart rate, body temperature, physical examination,
      electroencephalogram (EEG), laboratory safety assessments and adverse events. Sedation and
      psychomotor tests and a quantitative EEG will also be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.</measure>
    <time_frame>From screening up to 16 weeks</time_frame>
    <description>Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (cMax) of ODM-106</measure>
    <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.</time_frame>
    <description>cMax of ODM-106 after single dosing of either Capsule B or Capsule A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106</measure>
    <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level</time_frame>
    <description>AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax) of ODM-106</measure>
    <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level</time_frame>
    <description>tmax of ODM-106 after single oral dosing of Capsule B or Capsule A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-life of ODM-106</measure>
    <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.</time_frame>
    <description>Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite Screening in Plasma and Urine</measure>
    <time_frame>Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level</time_frame>
    <description>Metabolite screening in plasma and urine after single dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ODM-106 on Growth Hormone Levels</measure>
    <time_frame>Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.</time_frame>
    <description>Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation Scores on a Visual Analogue Scale (VAS)</measure>
    <time_frame>Pre-dose and at 1, 6 and 10.5h post dose at each dose level</time_frame>
    <description>Assessment of sedation by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dexterity and Reaction Times</measure>
    <time_frame>Pre-dose and at 1 and 6h post dose at each dose level</time_frame>
    <description>Selected battery of psychomotor tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative EEG</measure>
    <time_frame>Pre-dose and at 1, 6 and 10 h post dose at each dose level</time_frame>
    <description>Quantitative analysis of EEG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Drug: ODM-106</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsules dosage 2-800mg once daily for one day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsules given once daily for one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-106</intervention_name>
    <description>Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.</description>
    <arm_group_label>Drug: ODM-106</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.</description>
    <arm_group_label>Drug: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained.

          -  Participants must be able to speak, read and understand German.

          -  Good general health ascertained by detailed medical history and physical examinations.

          -  Males 18-45 years (inclusive).

          -  Body mass index (BMI) 18-30 kg/m2 inclusive

          -  Weight 55-95 kg (inclusive).

          -  Participants with female partners of child-bearing potential must adhere to a proper
             form of contraception from first study treatment administration until 3 months after
             the end-of-study visit.

        Exclusion Criteria:

          -  A predictable poor compliance or inability to understand and comply with protocol
             requirements, instructions and protocol-stated restrictions or communicate well with
             the investigator.

          -  Vulnerable subjects.

          -  Veins unsuitable for repeated venipuncture.

          -  Evidence of clinically relevant cardiovascular, renal, hepatic, haematological,
             gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or
             psychiatric disease as judged by the investigator. The participants should be healthy
             subjects.

          -  Subjects with a medical history of relevant psychiatric disorders or evidence of
             significant neuropsychiatric disease

          -  Any condition requiring regular concomitant medication including herbal products or
             likely to need any concomitant medication during the study.

          -  Definite or suspected personal history of hypersensitivity to drugs or excipients.

          -  Intake of any medication that could affect the outcome of the study, as judged by the
             investigator, within 2 weeks before first study treatment administration (2 months for
             enzyme inducing drugs like rifampicin or carbamazepin), or less than 5 times the
             half-life of the medication.

          -  A history of alcoholism or excess alcohol intake (including regular consumption of
             more than 21 units of alcohol per week) .

          -  Use of nicotine-containing products within 6 months of admission and inability to
             refrain from using nicotine-containing products during the study.

          -  History of drug abuse or positive drug screen for amphetamine, barbiturates,
             benzodiazepines, cannabinoids, cocaine, opiates, methamphetamine or methadone.

          -  Propensity to get headache when refraining from caffeine-containing beverages.

          -  Blood donation or loss of clinically relevant amount of blood within 2 months before
             the screening visit.

          -  Abnormal 12-lead ECG finding of clinical relevance at the screening visit

          -  Heart rate (HR) &lt; 50 bpm or &gt; 90 bpm after 10 min in rest (supine) at the screening
             visit

          -  At the screening visit: systolic BP &lt; 90 mmHg or &gt; 140 mmHg, diastolic BP &lt; 50 mmHg or
             &gt; 90 mmHg, orthostatic hypotension decrease of greater than or equal to 20 mmHg for
             systolic BP, decrease of greater than or equal to 10 mmHg for diastolic BP.

          -  Abnormal 24-h Holter of clinical relevance at the screening visit,

          -  Positive serology to human immunodeficiency virus (HIV) antibodies, hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies.

          -  Any abnormal value of laboratory, vital signs, or physical examination, which may in
             the opinion of the investigator interfere with the interpretation of the test results
             or cause a health risk for the subject if he takes part in the study.

          -  Participation in an investigational drug study within 2 months before entry into this
             study.

          -  An employee, a direct or indirect relative of the employee of the contract research
             organisation or the sponsor.

          -  Any other condition that in the opinion of the investigator would interfere with the
             evaluation of the results or constitute a health risk for the subject.

          -  Subject with abnormal standard EEG judged as clinically relevant by the investigator
             at screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International GmbH, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Whiteside</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2015</study_first_posted>
  <results_first_submitted>October 28, 2016</results_first_submitted>
  <results_first_submitted_qc>October 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2016</results_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy male volunteers were recruited</recruitment_details>
      <pre_assignment_details>Screening : Male subjects were screened and following PE, vital signs, EEG, ECG and lab. assessments were randomised into the study.
Sixteen subjects were randomised to 2 panels of 8, each subject received 3 single doses of ODM-106 and 1 dose of placebo in a randomised crossover design.
Panel 1 was completed before Panel 2 commenced dosing.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Panel 1</title>
          <description>Single oral doses ODM-106 Capsule B: 2, 10, 25, 50 mg , placebo</description>
        </group>
        <group group_id="P2">
          <title>Panel 2</title>
          <description>Single oral doses ODM-106 Capsule B: 100, 100, 200mg. ODM-106 Capsule A 100 mg , placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Period 1</title>
              <participants_list>
                <participants group_id="P1" count="8">6 subjects ODM-106 Capsule B 2 mg and 2 subjects on placebo</participants>
                <participants group_id="P2" count="8">6 subjects ODM-106 Capsule B 100 mg (1 x 100mg) and 2 subjects on placebo</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Period 2</title>
              <participants_list>
                <participants group_id="P1" count="8">6 subjects ODM-106 Capsule B 10 mg and 2 subjects on placebo</participants>
                <participants group_id="P2" count="8">6 subjects ODM-106 Capsule B 100 mg (10 x 10mg) and 2 subjects on placebo</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Period 3</title>
              <participants_list>
                <participants group_id="P1" count="8">6 subjects ODM-106 Capsule B 25 mg and 2 subjects on placebo</participants>
                <participants group_id="P2" count="8">6 subjects ODM-106 Capsule B 200 mg (20 x 10mg) and 2 subjects on placebo</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Period 4</title>
              <participants_list>
                <participants group_id="P1" count="8">6 subjects ODM-106 Capsule B 50 mg and 2 subjects on placebo</participants>
                <participants group_id="P2" count="8">6 subjects ODM-106 Capsule A 100 mg (10 x 10mg) and 2 subjects on placebo</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panel 1</title>
          <description>Single oral doses ODM-106 Capsule B 2, 10, 25, 50mg, placebo</description>
        </group>
        <group group_id="B2">
          <title>Panel 2</title>
          <description>Single oral doses ODM-106 Capsule B 100, 100, 200 mg. ODM-106 Capsule A 100mg, placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.</title>
        <description>Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.</description>
        <time_frame>From screening up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ODM-106 Capsule B 2mg</title>
            <description>Single oral dose 2 x 1 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O2">
            <title>ODM-106 Capsule B 10mg</title>
            <description>Single oral dose 2 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O3">
            <title>ODM-106 Capsule B 25mg</title>
            <description>Single oral dose 2 x 10mg 1 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O4">
            <title>ODM-106 Capsule B 50mg</title>
            <description>Single oral dose 5 x 10mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O5">
            <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
            <description>Single oral dose 1 x 100mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O6">
            <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
            <description>Single oral dose 10 x 10mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O7">
            <title>ODM-106 Capsule B 200mg</title>
            <description>Single oral dose 20 x 10mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O8">
            <title>ODM-106 Capsule A 100mg</title>
            <description>Single oral dose 10 x 10mg ODM-106 Capsule A</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>2 placebo subjects per Arm with matched number of placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety. Number of Participants With Adverse Events Related to Tolerability.</title>
          <description>Clinically relevant changes from baseline in safety laboratory assessments (haematology, clinical chemistry, urinalysis), vital signs (pulse and heart rate), 12 lead electrocardiograms, Holter electrocardiograms, telemetry, physical examination.</description>
          <units>subjects affected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Plasma Concentration (cMax) of ODM-106</title>
        <description>cMax of ODM-106 after single dosing of either Capsule B or Capsule A</description>
        <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ODM-106 Capsule B 2mg</title>
            <description>Single oral dose 2 x 1 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O2">
            <title>ODM-106 Capsule B 10mg</title>
            <description>Single oral dose 2 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O3">
            <title>ODM-106 Capsule B 25mg</title>
            <description>Single oral dose 2 x 10 mg and 1 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O4">
            <title>ODM-106 Capsule B 50mg</title>
            <description>Single oral dose 5 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O5">
            <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
            <description>Single oral dose 1 x 100 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O6">
            <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O7">
            <title>ODM-106 Capsule B 200mg</title>
            <description>Single oral dose 20 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O8">
            <title>ODM-106 Capsule A 100mg</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule A</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>2 placebo subjects per Arm with matched number of placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (cMax) of ODM-106</title>
          <description>cMax of ODM-106 after single dosing of either Capsule B or Capsule A</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="4.2"/>
                    <measurement group_id="O2" value="18.4" spread="11.4"/>
                    <measurement group_id="O3" value="67.8" spread="51.7"/>
                    <measurement group_id="O4" value="119.2" spread="60.1"/>
                    <measurement group_id="O5" value="22.0" spread="20.1"/>
                    <measurement group_id="O6" value="225.9" spread="177.2"/>
                    <measurement group_id="O7" value="547.7" spread="319.5"/>
                    <measurement group_id="O8" value="8.3" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106</title>
        <description>AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.</description>
        <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine sampling, pre-dose and for 24 hours post dose at each dose level</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ODM-106 Capsule B 2mg</title>
            <description>Single oral dose 2 x 1 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O2">
            <title>ODM-106 Capsule B 10mg</title>
            <description>Single oral dose 2 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O3">
            <title>ODM-106 Capsule B 25mg</title>
            <description>Single oral dose 2 x 10 mg and 1 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O4">
            <title>ODM-106 Capsule B 50mg</title>
            <description>Single oral dose 5 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O5">
            <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
            <description>Single oral dose 1 x 100 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O6">
            <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O7">
            <title>ODM-106 Capsule B 200mg</title>
            <description>Single oral dose 20 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O8">
            <title>ODM-106 Capsule A 100mg</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule A</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>2 placebo subjects per Arm with matched number of placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) of ODM-106</title>
          <description>AUC of ODM-106 after single oral dosing of either Capsule B or Capsule A.</description>
          <units>h*ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="8.8"/>
                    <measurement group_id="O2" value="61.3" spread="44.1"/>
                    <measurement group_id="O3" value="213.8" spread="78.7"/>
                    <measurement group_id="O4" value="559.4" spread="310.9"/>
                    <measurement group_id="O5" value="297.4" spread="346.3"/>
                    <measurement group_id="O6" value="1089.2" spread="977.0"/>
                    <measurement group_id="O7" value="2850.8" spread="2319.8"/>
                    <measurement group_id="O8" value="82.0" spread="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Plasma Concentration (Tmax) of ODM-106</title>
        <description>tmax of ODM-106 after single oral dosing of Capsule B or Capsule A</description>
        <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ODM-106 Capsule B 2mg</title>
            <description>Single oral dose 2 x 1 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O2">
            <title>ODM-106 Capsule B 10mg</title>
            <description>Single oral dose 2 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O3">
            <title>ODM-106 Capsule B 25mg</title>
            <description>Single oral dose 2 x 10 mg 1 x 5mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O4">
            <title>ODM-106 Capsule B 50mg</title>
            <description>Single oral dose 5 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O5">
            <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
            <description>Single oral dose 1 x 100 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O6">
            <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O7">
            <title>ODM-106 Capsule B 200mg</title>
            <description>Single oral dose 20 x 10 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O8">
            <title>ODM-106 Capsule A 100mg</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule A.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>2 placebo subjects per Arm with matched number of placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Concentration (Tmax) of ODM-106</title>
          <description>tmax of ODM-106 after single oral dosing of Capsule B or Capsule A</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.5" upper_limit="1.0"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.5" upper_limit="3.0"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.5" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.8" upper_limit="3.5"/>
                    <measurement group_id="O5" value="5.8" lower_limit="1.5" upper_limit="23.9"/>
                    <measurement group_id="O6" value="1.5" lower_limit="0.8" upper_limit="3.5"/>
                    <measurement group_id="O7" value="1.5" lower_limit="0.8" upper_limit="3.5"/>
                    <measurement group_id="O8" value="3.0" lower_limit="1.5" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-life of ODM-106</title>
        <description>Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A</description>
        <time_frame>Pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ODM-106 Capsule B 2mg</title>
            <description>Single oral dose 2 x 1 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O2">
            <title>ODM-106 Capsule B 10mg</title>
            <description>Single oral dose 2 x 5 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O3">
            <title>ODM-106 Capsule B 25mg</title>
            <description>Single oral dose 2 x 10 mg 1 x 5 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O4">
            <title>ODM-106 Capsule B 50mg</title>
            <description>Single oral dose 5 x 10 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O5">
            <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
            <description>Single oral dose 1 x 100 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O6">
            <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O7">
            <title>ODM-106 Capsule B 200mg</title>
            <description>Single oral dose 20 x 10 mg ODM-106 Capsule B.</description>
          </group>
          <group group_id="O8">
            <title>ODM-106 Capsule A 100mg</title>
            <description>Single oral dose 10 x 10 mg ODM-106 Capsule A.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>2 placebo subjects per Arm with matched number of placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life of ODM-106</title>
          <description>Elimination half-life of ODM-106 after single dosing of either Capsule B or Capsule A</description>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="5.5"/>
                    <measurement group_id="O2" value="20.6" spread="12.7"/>
                    <measurement group_id="O3" value="23.0" spread="2.1"/>
                    <measurement group_id="O4" value="27.3" spread="4.7"/>
                    <measurement group_id="O5" value="23.5" spread="6.3"/>
                    <measurement group_id="O6" value="27.4" spread="9.2"/>
                    <measurement group_id="O7" value="32.1" spread="10.0"/>
                    <measurement group_id="O8" value="21.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metabolite Screening in Plasma and Urine</title>
        <description>Metabolite screening in plasma and urine after single dosing</description>
        <time_frame>Plasma samples at pre-dose and 15, 30 and 45 min, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72 and 96 hours post dose at each dose level. Urine samples, pre-dose and for 24 hours post dose at each dose level</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of ODM-106 on Growth Hormone Levels</title>
        <description>Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.</description>
        <time_frame>Predose and 1, 2, 3,4, 6 and 8 hours post dose at each dose level.</time_frame>
        <population>Only timepoints 2 - 6h evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>ODM-106 Capsule B 2mg</title>
            <description>Single oral dose 2 x 1 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O2">
            <title>ODM-106 Capsule B 10mg</title>
            <description>Single oral dose 2 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O3">
            <title>ODM-106 Capsule B 25mg</title>
            <description>Single oral dose 2 x 10mg 1 x 5 mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O4">
            <title>ODM-106 Capsule B 50mg</title>
            <description>Single oral dose 5 x 10mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O5">
            <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
            <description>Single oral dose 1 x 100mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O6">
            <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
            <description>Single oral dose 10 x 10mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O7">
            <title>ODM-106 Capsule B 200mg</title>
            <description>Single oral dose 20 x 10mg ODM-106 Capsule B</description>
          </group>
          <group group_id="O8">
            <title>ODM-106 Capsule A 100mg</title>
            <description>Single oral dose 10 x 10mg ODM-106 Capsule A</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>2 placebo subjects per Arm with matched number of placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of ODM-106 on Growth Hormone Levels</title>
          <description>Growth hormone levels (Cmax) in serum after single oral dosing with either ODM-106 Capsule B, ODM-106 Capsule A or placebo.</description>
          <population>Only timepoints 2 - 6h evaluated.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.2"/>
                    <measurement group_id="O2" value="0.47" spread="1.04"/>
                    <measurement group_id="O3" value="1.05" spread="2.88"/>
                    <measurement group_id="O4" value="1.93" spread="1.99"/>
                    <measurement group_id="O5" value="0.8" spread="1.36"/>
                    <measurement group_id="O6" value="2.23" spread="6.12"/>
                    <measurement group_id="O7" value="0.82" spread="0.68"/>
                    <measurement group_id="O8" value="4.14" spread="4.96"/>
                    <measurement group_id="O9" value="1.01" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sedation Scores on a Visual Analogue Scale (VAS)</title>
        <description>Assessment of sedation by subject</description>
        <time_frame>Pre-dose and at 1, 6 and 10.5h post dose at each dose level</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dexterity and Reaction Times</title>
        <description>Selected battery of psychomotor tests</description>
        <time_frame>Pre-dose and at 1 and 6h post dose at each dose level</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantitative EEG</title>
        <description>Quantitative analysis of EEG</description>
        <time_frame>Pre-dose and at 1, 6 and 10 h post dose at each dose level</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of study treatment until the end of study visit (approximately 12-16 weeks)</time_frame>
      <desc>16 subjects were randomised into 2 panels of 8 subjects. Each panel of 8 subjects participated in 4 periods as a crossover, during each period 6 subjects received active and 2 subjects received placebo, There was a 2 week washout between each period.</desc>
      <group_list>
        <group group_id="E1">
          <title>ODM-106 Capsule B 2mg</title>
          <description>Single oral dose 2 x 1 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E2">
          <title>ODM-106 Capsule B 10mg</title>
          <description>Single oral dose 2 x 5 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E3">
          <title>ODM-106 Capsule B 25mg</title>
          <description>Single oral dose 2 x 10 mg 1 x 5 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E4">
          <title>ODM-106 Capsule B 50mg</title>
          <description>Single oral dose 5 x 10 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E5">
          <title>ODM-106 Capsule B 100mg (1 x 100mg)</title>
          <description>Single oral dose 1 x 100 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E6">
          <title>ODM-106 Capsule B 100mg (10 x 10mg)</title>
          <description>Single oral dose 10 x 10 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E7">
          <title>ODM-106 Capsule B 200mg</title>
          <description>Single oral dose 20 x 10 mg ODM-106 Capsule B</description>
        </group>
        <group group_id="E8">
          <title>ODM-106 Capsule A 100mg</title>
          <description>Single oral dose 10 x 10 mg ODM-106 Capsule A</description>
        </group>
        <group group_id="E9">
          <title>Placebo</title>
          <description>2 placebo subjects per Arm with matched number of placebo capsules</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>RHYTHM IDIOVENTRICULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NASAL HERPES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SUNBURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>NASAL DRYNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Information Desk</name_or_title>
      <organization>Orion Corporation</organization>
      <phone>+358104261</phone>
      <email>clinicaltrials@orionpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

